MedPath

Robotic vs. Open NSM for Early Stage Breast Cancer

Not Applicable
Recruiting
Conditions
Breast Cancer
Breast Cancer, Early-Onset
Breast
Breast Cancer Female
Breast Disease
Registration Number
NCT05720039
Lead Sponsor
Intuitive Surgical
Brief Summary

This study evaluates the safety and effectiveness of the da Vinci SP Surgical System compared to Open NSM in Nipple Sparing Mastectomy procedures.

Detailed Description

This study is a prospective, two-arm, multi-center, randomized controlled clinical investigation between RSNM and open NSM.

This study evaluates the safety and effectiveness of the da Vinci SP Surgical System compared to Open NSM in Nipple Sparing Mastectomy procedures.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
204
Inclusion Criteria
  • Female age 21 or older
  • BMI < 30
  • Candidate for an NSM procedure with immediate reconstruction
  • Diagnosis of early stage brest cancer
  • Breast ptosis ≤ Grade 2.
  • Cup size ≤ C.
Exclusion Criteria
  • Previous breast surgery
  • Diagnosis of metastatic breast cancer
  • Prior radiation treatment to the chest
  • Current smokers
  • Contraindication for general anesthesia or surgery.
  • Known bleeding or clotting disorder.
  • Pregnant or suspected to be pregnant, or actively breastfeeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Safety: Adverse event ratesUp to 42 days post-operatively

Incidence of intraoperative and post-operative procedure and device-related adverse events compared to open NSM

Conversion rateAssessed during procedure

Conversion is defined as conversion of da Vinci Xi robotic-assisted surgery to open surgery

Safety: positive surgical margin ratesUp to 42 days post-operatively

Incidence of positive surgical margins compared to open NSM

Secondary Outcome Measures
NameTimeMethod
Patient-Report Outcomes (BREAST-Q)Up to 5 years

BREAST-Q

Oncological Outcomes (for cancer recurrence)Up to 5 years

Recurrence

Oncological Outcomes (for disease-free survival)Up to 5 years

Disease-free survival

Oncological Outcomes (for overall survival)Up to 5 years

Overall survival

Patient-Report Outcomes (NAC Questionnaire)Up to 5 years

NAC Questionnaire

Patient-Report Outcomes (EQ-5D)Up to 1 year

EQ-5D

Trial Locations

Locations (15)

City of Hope

🇺🇸

Irvine, California, United States

Cedars-Sinai

🇺🇸

Los Angeles, California, United States

Mayo Clinic Florida

🇺🇸

Jacksonville, Florida, United States

Emory University

🇺🇸

Atlanta, Georgia, United States

Endeavor Health

🇺🇸

Evanston, Illinois, United States

Corewell

🇺🇸

Detroit, Michigan, United States

Mayo Clinic Rochester

🇺🇸

Rochester, Minnesota, United States

Washington University, St. Louis

🇺🇸

St. Louis, Missouri, United States

Northwell Health

🇺🇸

Lake Success, New York, United States

Duke University

🇺🇸

Durham, North Carolina, United States

Scroll for more (5 remaining)
City of Hope
🇺🇸Irvine, California, United States
Jenny Sanchez
Contact
949-671-4057
jesanchez@coh.org
Stephanie Casal, MS, RN, CNS
Contact
949-671-4112
scasal@coh.org
Jennifer Tseng, MD
Contact
Jamie Rand, MD
Contact
Mouchammed Agko, MD
Contact
Antoine Carre, MD
Contact
Katharine Schulz-Costello, DO
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.